A clinical trial has produced encouraging results for a new Alzheimer's disease treatment. The experimental drug, developed by Biogen and Eisai, reduced cognitive decline by 35% compared to placebo in patients with early-stage Alzheimer's.
The study involved 1,200 participants across multiple medical centers. Patients receiving the treatment showed slower progression of memory loss and maintained better daily functioning. Brain scans revealed reduced levels of amyloid plaques, protein clusters associated with Alzheimer's pathology.
Dr. Maria Carrillo, chief science officer at the Alzheimer's Association, called the results "promising" but cautioned that more research is needed. "This represents progress, but we must continue to pursue multiple approaches to addressing this devastating disease," she stated.